Literature DB >> 30582586

A Chromatin Immunoprecipitation Assay to Identify Novel NFAT2 Target Genes in Chronic Lymphocytic Leukemia.

Alexander R Fuchs1, Melanie Märklin1, Jonas S Heitmann1, Stefan Futterknecht1, Michael Haap2, Stefan Wirths1, Hans-Georg Kopp1, Clemens Hinterleitner1, Daniela Dörfel1, Martin R Müller3.   

Abstract

Chronic lymphocytic leukemia (CLL) is characterized by the expansion of malignant B cell clones and represents the most common leukemia in western countries. The majority of CLL patients show an indolent course of the disease as well as an anergic phenotype of their leukemia cells, referring to a B cell receptor unresponsive to external stimulation. We have recently shown that the transcription factor NFAT2 is a crucial regulator of anergy in CLL. A major challenge in the analysis of the role of a transcription factor in different diseases is the identification of its specific target genes. This is of great significance for the elucidation of pathogenetic mechanisms and potential therapeutic interventions. Chromatin immunoprecipitation (ChIP) is a classic technique to demonstrate protein-DNA interactions and can, therefore, be used to identify direct target genes of transcription factors in mammalian cells. Here, ChIP was used to identify LCK as a direct target gene of NFAT2 in human CLL cells. DNA and associated proteins are crosslinked using formaldehyde and subsequently sheared by sonication into DNA fragments of approximately 200-500 base pairs (bp). Cross-linked DNA fragments associated with NFAT2 are then selectively immunoprecipitated from cell debris using an αNFAT2 antibody. After purification, associated DNA fragments are detected via quantitative real-time PCR (qRT-PCR). DNA sequences with evident enrichment represent regions of the genome which are targeted by NFAT2 in vivo. Appropriate shearing of the DNA and the selection of the required antibody are particularly crucial for the successful application of this method. This protocol is ideal for the demonstration of direct interactions of NFAT2 with target genes. Its major limitation is the difficulty to employ ChIP in large-scale assays analyzing the target genes of multiple transcription factors in intact organisms.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30582586     DOI: 10.3791/58270

Source DB:  PubMed          Journal:  J Vis Exp        ISSN: 1940-087X            Impact factor:   1.355


  5 in total

1.  Automated spheroid generation, drug application and efficacy screening using a deep learning classification: a feasibility study.

Authors:  Leo Benning; Andreas Peintner; Günter Finkenzeller; Lukas Peintner
Journal:  Sci Rep       Date:  2020-07-06       Impact factor: 4.379

2.  Cells grown in three-dimensional spheroids mirror in vivo metabolic response of epithelial cells.

Authors:  Simon Lagies; Manuel Schlimpert; Simon Neumann; Astrid Wäldin; Bernd Kammerer; Christoph Borner; Lukas Peintner
Journal:  Commun Biol       Date:  2020-05-19

3.  Novel integrated workflow allows production and in-depth quality assessment of multifactorial reprogrammed skeletal muscle cells from human stem cells.

Authors:  Brigitte M Pützer; Alf Spitschak; Dinis Faustino; Heinrich Brinkmeier; Stella Logotheti; Anika Jonitz-Heincke; Hande Yilmaz; Isil Takan; Kirsten Peters; Rainer Bader; Hermann Lang; Athanasia Pavlopoulou
Journal:  Cell Mol Life Sci       Date:  2022-04-09       Impact factor: 9.261

4.  Genetic Loss of LCK Kinase Leads to Acceleration of Chronic Lymphocytic Leukemia.

Authors:  Melanie Märklin; Alexander R Fuchs; Claudia Tandler; Jonas S Heitmann; Helmut R Salih; Joseph Kauer; Leticia Quintanilla-Martinez; Stefan Wirths; Hans-Georg Kopp; Martin R Müller
Journal:  Front Immunol       Date:  2020-09-02       Impact factor: 7.561

5.  Downregulation of miR-199a-3p mediated by the CtBP2-HDAC1-FOXP3 transcriptional complex contributes to acute lung injury by targeting NLRP1.

Authors:  Zhi Chen; Wei-Hua Dong; Qiang Chen; Qiu-Gen Li; Zhong-Min Qiu
Journal:  Int J Biol Sci       Date:  2019-09-08       Impact factor: 6.580

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.